Here are the DEF 14A proxy statements from Sonoma Pharmaceuticals, Inc. (SNOA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SNOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNOA filings page.
Sonoma Pharmaceuticals is soliciting proxies for its 2026 Annual Meeting on September 16, 2026 at 2:00 p.m. MDT at its Boulder, Colorado office. Stockholders of record at the close of business on July 24, 2026, when 4,788,425 shares of common stock were outstanding, may vote.
Stockholders are asked to elect one Class III director (Jerry McLaughlin), approve on an advisory basis 2026 executive compensation, ratify Frazier & Deeter, LLC as auditor for fiscal 2027, and authorize possible adjournment to solicit additional proxies. The filing details a classified, majority-independent board, committee structure, and director pay.
For fiscal 2026, CEO Amy Trombly received total compensation of $741,116, and CFO Jerry Dvonch received $422,679, combining salary, cash bonuses and equity. An amended CEO employment agreement provides base salary of $475,000, a 50% target bonus and significant severance and change-of-control protections. Pay-versus-performance disclosure shows 2026 “compensation actually paid” versus a net loss of $3,175 thousand and a total shareholder return value of $10.91 on an initial $100 investment.
Sonoma Pharmaceuticals, Inc. is asking stockholders to approve a reincorporation from Delaware to Nevada and authority to adjourn the special meeting if needed. The board cites eliminating roughly $200,000 in annual Delaware franchise taxes, replacing them with Nevada fees of about $650, and broader director and officer liability protections.
The move would not change existing ownership, as each Delaware common share would convert into one Nevada common share. Stockholders of record on April 28, 2026, when 3,473,554 common shares were outstanding, may vote in person or by proxy at the June 24, 2026 special meeting.